BibTex RIS Cite

-

Year 2013, Volume: 26 Issue: 1 , 17 - 20 , 30.09.2015

Züleyha Özgen Oya Gürbüz

https://izlik.org/JA53GK85PT

Abstract

Objective: To compare the efficacy of nadifloxacin alone and with benzoyl peroxide in the treatment of mild to moderate facial acne vulgaris. Patients and Methods: This double-blind, randomized study was conducted in a total of 93 acne patients, with at least 10 inflammatory lesions, but no more than 3 nodules or cysts on the face. All patients were instructed to apply nadifloxacin 1% cream twice daily and randomized to apply either benzoyl peroxide 5% lotion or its vehicle once daily for 8 weeks. Results: The mean percent reduction in inflammatory lesions were 22.08% in the nadifloxacin group (n=46) and 53.5% in the nadifloxacin+benzoyl peroxide group (n=47). Five (10.9%) patients in the nadifloxacin group and 18 (38.3%) patients in the nadifloxacin+benzoyl peroxide group achieved a 50% and greater reduction in the inflammatory lesion count. Conclusion: Both treatment regimens were statistically effective, but a significantly greater reduction of the inflammatory lesions was seen in the nadifloxacin+benzoyl peroxide group. The number of patients who achieved a 50% and greater reduction in inflammatory lesion count was significantly higher in the nadifloxacin+benzoyl peroxide group. Both treatment regimens were well tolerated with mild side effects

Keywords

Acne Nadifloxacin Benzoyl peroxide

References

  • 1. Thiboutat D, Gollnick H, Bettoli V, et al. New insights into the managements of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009; 60 (5 Suppl): S1- 50. doi: 10.1016/j.jaad.2009.01.019
  • 2. Gollnick H, Cunliffe W, Berson D, et al. Global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1-37.
  • 3. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339-46. doi:10.1046/j.1365-2133.2001.03956.x
  • 4. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes in acne. Cutis 2001; 67 (2 suppl): 21-4.
  • 5. Coates P, Vyakrnam S, Eady EA, et al. Prevelance of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distrubution study. Br J Dermatol 2002; 146: 840-8. doi:10.1046/j.1365-2133.2002.04690.x
  • 6. Kawabata S, Ohguro K, Mukai F, et al. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: In vitro antibacterial activity. Chemotherapy 1989; 37: 1160-78.
  • 7. Kurukawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evalution of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J am Acad Dermatol 1991; 25: 674-81.
  • 8. Jung JY, Kwan HH, Yeau KB, et al. Clinical and histological evalution of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011; 50:350-7. doi:10.1111/j.1365- 4632.2010.04701.x
  • 9. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a doubleblind, phase 3 comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16 : 48-55. doi:10.1586/17469872.1.5.643
  • 10. Tunca M, Akar A, Ozmen I, et al. Topical nadifloxacin 1% cream vs. topical erythromycin 4% jel in the treatment of mild to moderate acne. Int J Dermatol 2010; 45:1440-4. doi:10.1111/j.1365- 4632.2010.04601.x
  • 11. Bojar RA, Hittel N, Cunliffe WJ, et al. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49 (Suppl 2): 164- 7.
  • 12. Alba V, Urban E, Dominguez A, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analsis of the possible evalution of resistance after 2 years of use in Germany. Int J Antimicrob Agent 2009; 33: 272-5. doi:10.1016/j.ijantimicag.2008.08.024
  • 13. Thiboutat D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 6: 1-9.
  • 14. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, doubleblind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006, 54: 73-81. doi:10.1016/j.jaad.2005.04.046
  • 15. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395-403.
  • 16. Eady EA, Cove JH, Joanes DN. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of literature on their clinical benefit and comparative efficacy. J Dermatolog Treat 1990; 1: 215-26. doi:10.3109/09546639009086737
  • 17. Thiboutot D, Weiss J, Bucko A, Jones T. Adapalene-benzoyl peroxide, a fixed dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-9. doi:10.1016/j.jaad.2007.06.006
  • 18. Cunliffe WJ, Holland KT, Bojar R. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117-33. doi:10.1016/S0149- 2918(02)80023-6
  • 19. Ozolins M, Eady EA, Avery A, Cunliffe WJ. Comparison of five antimicrobial regimens for the treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet 2004; 364: 2188-95. doi:10.1016/S0140- 6736(04)17591-0
  • 20. Ghali F, Kang S, Leyden JJ, et al. Changing the face of acne therapy. Cutis 2009; 83 (2 Suppl): 4-15.
  • 21. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. JDDG 2006; 4: 293-300. doi:10.1111/ j.1610-0387.2006.05931suppl.x

Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması

Year 2013, Volume: 26 Issue: 1 , 17 - 20 , 30.09.2015

Züleyha Özgen Oya Gürbüz

https://izlik.org/JA53GK85PT

Abstract

Amaç: Hafif-orta şiddetli akne vulgaris tedavisinde nadifloksasin
kremin tek başına veya benzoil peroksit ile birlikte kullanımının
etkinliğini karşılaştırma.
Hastalar ve Yöntem: Çift kör, randomize çalışma, toplam
93 hasta 2 grup olarak ya nadifloksasin kremi ya benzoil peroksit
losyonun baz formu ya da benzoil peroksit ile birlikte 8 hafta süre
ile kullandı.
Bulgular: İnflamatuar lezyonlar tek başına nadifloksasin
kullanan grupta(n=46) %22, 08, nadifloksasin+benzoil peroksit
kullanan grupta(n=47) %53,5 oranında azaldı. Tek başına
nadifloksasin kullanan grupta beş (%10,9), nadifloksasin+benzoil
peroksit kullanan grupta 18(%38,3)hastada inflamatuar lezyonlarda
%50 ve üzeri azalma görüldü.
Sonuç: Her iki tedavi de istatistiksel olarak etkili bulundu ancak
nadifloksasin+benzoil peroksit grubunda belirgin olarak inflamatuar
lezyonlarda azalma görüldü. Her iki tedavi de hafif yan etkiler ile
çok iyi tolere edildi

Keywords

Akne Nadifloksasin Benzoil peroksit

References

  • 1. Thiboutat D, Gollnick H, Bettoli V, et al. New insights into the managements of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009; 60 (5 Suppl): S1- 50. doi: 10.1016/j.jaad.2009.01.019
  • 2. Gollnick H, Cunliffe W, Berson D, et al. Global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1-37.
  • 3. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339-46. doi:10.1046/j.1365-2133.2001.03956.x
  • 4. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes in acne. Cutis 2001; 67 (2 suppl): 21-4.
  • 5. Coates P, Vyakrnam S, Eady EA, et al. Prevelance of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distrubution study. Br J Dermatol 2002; 146: 840-8. doi:10.1046/j.1365-2133.2002.04690.x
  • 6. Kawabata S, Ohguro K, Mukai F, et al. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: In vitro antibacterial activity. Chemotherapy 1989; 37: 1160-78.
  • 7. Kurukawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evalution of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J am Acad Dermatol 1991; 25: 674-81.
  • 8. Jung JY, Kwan HH, Yeau KB, et al. Clinical and histological evalution of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011; 50:350-7. doi:10.1111/j.1365- 4632.2010.04701.x
  • 9. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a doubleblind, phase 3 comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16 : 48-55. doi:10.1586/17469872.1.5.643
  • 10. Tunca M, Akar A, Ozmen I, et al. Topical nadifloxacin 1% cream vs. topical erythromycin 4% jel in the treatment of mild to moderate acne. Int J Dermatol 2010; 45:1440-4. doi:10.1111/j.1365- 4632.2010.04601.x
  • 11. Bojar RA, Hittel N, Cunliffe WJ, et al. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49 (Suppl 2): 164- 7.
  • 12. Alba V, Urban E, Dominguez A, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analsis of the possible evalution of resistance after 2 years of use in Germany. Int J Antimicrob Agent 2009; 33: 272-5. doi:10.1016/j.ijantimicag.2008.08.024
  • 13. Thiboutat D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 6: 1-9.
  • 14. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, doubleblind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006, 54: 73-81. doi:10.1016/j.jaad.2005.04.046
  • 15. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395-403.
  • 16. Eady EA, Cove JH, Joanes DN. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of literature on their clinical benefit and comparative efficacy. J Dermatolog Treat 1990; 1: 215-26. doi:10.3109/09546639009086737
  • 17. Thiboutot D, Weiss J, Bucko A, Jones T. Adapalene-benzoyl peroxide, a fixed dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-9. doi:10.1016/j.jaad.2007.06.006
  • 18. Cunliffe WJ, Holland KT, Bojar R. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117-33. doi:10.1016/S0149- 2918(02)80023-6
  • 19. Ozolins M, Eady EA, Avery A, Cunliffe WJ. Comparison of five antimicrobial regimens for the treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet 2004; 364: 2188-95. doi:10.1016/S0140- 6736(04)17591-0
  • 20. Ghali F, Kang S, Leyden JJ, et al. Changing the face of acne therapy. Cutis 2009; 83 (2 Suppl): 4-15.
  • 21. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. JDDG 2006; 4: 293-300. doi:10.1111/ j.1610-0387.2006.05931suppl.x
There are 21 citations in total.

Details

Primary Language Turkish
Authors

Züleyha Özgen This is me

Oya Gürbüz This is me

Publication Date September 30, 2015
IZ https://izlik.org/JA53GK85PT
Published in Issue Year 2013 Volume: 26 Issue: 1

Cite

APA Özgen, Z., & Gürbüz, O. (2015). Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Medical Journal, 26(1), 17-20. https://izlik.org/JA53GK85PT
AMA 1.Özgen Z, Gürbüz O. Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Med J. 2015;26(1):17-20. https://izlik.org/JA53GK85PT
Chicago Özgen, Züleyha, and Oya Gürbüz. 2015. “Hafif-Orta şiddetli Akne Vulgaris Yüz Tutulumu Tedavisinde Nadifloksasinin Tek Başına Ve Benzoil Peroksit Ile Birlikte Kullanımının Karşılaştırılması”. Marmara Medical Journal 26 (1): 17-20. https://izlik.org/JA53GK85PT.
EndNote Özgen Z, Gürbüz O (October 1, 2015) Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Medical Journal 26 1 17–20.
IEEE [1]Z. Özgen and O. Gürbüz, “Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması”, Marmara Med J, vol. 26, no. 1, pp. 17–20, Oct. 2015, [Online]. Available: https://izlik.org/JA53GK85PT
ISNAD Özgen, Züleyha - Gürbüz, Oya. “Hafif-Orta şiddetli Akne Vulgaris Yüz Tutulumu Tedavisinde Nadifloksasinin Tek Başına Ve Benzoil Peroksit Ile Birlikte Kullanımının Karşılaştırılması”. Marmara Medical Journal 26/1 (October 1, 2015): 17-20. https://izlik.org/JA53GK85PT.
JAMA 1.Özgen Z, Gürbüz O. Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Med J. 2015;26:17–20.
MLA Özgen, Züleyha, and Oya Gürbüz. “Hafif-Orta şiddetli Akne Vulgaris Yüz Tutulumu Tedavisinde Nadifloksasinin Tek Başına Ve Benzoil Peroksit Ile Birlikte Kullanımının Karşılaştırılması”. Marmara Medical Journal, vol. 26, no. 1, Oct. 2015, pp. 17-20, https://izlik.org/JA53GK85PT.
Vancouver 1.Züleyha Özgen, Oya Gürbüz. Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması. Marmara Med J [Internet]. 2015 Oct. 1;26(1):17-20. Available from: https://izlik.org/JA53GK85PT